



CODEN [USA]: IAJPBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.1336776>Available online at: <http://www.iajps.com>

Research Article

**ANALYSIS OF DRUG-INDUCED LIVER INJURY BY  
AMOXICILLIN WITH THE COMPARISON OF  
CLAVULANATE: A CASE CONTROL STUDY**<sup>1</sup>Dr. Zeeshan Afzal, <sup>2</sup>Dr. Hammad Rafiq, <sup>3</sup>Dr. Muhammad Yasir<sup>1</sup>Medical Officer at RHC Feroza, Liaquatpur, Rahim Yar Khan<sup>2</sup>Medical Officer at RHC Bagho Bahar, Khanpur, Rahim Yar Khan<sup>3</sup>Medical Officer at RHC Nawazabad, Sadiq Abad, Rahim Yar Khan**Abstract:**

**Introduction:** Drug-induced liver injury (DILI) is an important differential diagnosis in patients with abnormal liver tests and normal hepatobiliary imaging. Of all known liver diseases, the diagnosis of DILI is probably one of the most difficult one to be established. **Objectives of the study:** The main objective of the study is to find the drug induced liver injury in hepatic patients with special reference to Amoxicillin with the comparison of Clavulanate. **Methodology of the study:** This study was conducted at the hospitals of Rahim Yar Khan, Pakistan during 2017 with the permission of ethical committee of hospital. For this purpose we select the 20 patients who was suffering from chronic hepatic injury due to the excessive use of drugs especially Amoxicillin and Clavulanate. **Results:** We analyzed 20 cases matched to controls. Seven cases were exposed to amoxicillin (adjusted OR 1.69, 95% CI 0.72-3.98) and 13 cases to co-amoxiclav (adjusted OR 3.00, 95% CI 1.76-5.40). **Conclusion:** It is concluded that compared to amoxicillin alone, amoxicillin +clavulanic acid doubles the risk of serious acute liver injury, in agreement with most studies on DILI.

**\* Corresponding author:****Dr. Zeeshan Afzal,**

Medical Officer at RHC Feroza,

Liaquatpur, Rahim Yar Khan

QR code



Please cite this article in press Zeeshan Afzal et al., *Analysis of Drug-Induced Liver Injury by Amoxicillin with the Comparison of Clavulanate: A Case Control Study.*, Indo Am. J. P. Sci, 2018; 05(08).

**INTRODUCTION:**

Drug-induced liver injury (DILI) is an important differential diagnosis in patients with abnormal liver tests and normal hepatobiliary imaging. Of all known liver diseases, the diagnosis of DILI is probably one of the most difficult one to be established. In all major studies on DILI, antibiotics are the most common type of drugs that have been reported [1]. The clinical phenotype of different types of antibiotics associated with liver injury is highly variable. Some widely used antibiotics such as amoxicillin vs clavulanate have been shown to have a delayed onset on liver injury and recently cefazolin has been found to lead to liver injury 1–3 weeks after exposure of a single infusion [2]. The other extreme is the nature of nitrofurantoin-induced liver injury, which can occur after a few years of treatment and lead to acute liver failure (ALF) or autoimmune-like reaction. Most patients with liver injury associated with use of antibiotics have a favorable prognosis [3]. However, patients with jaundice have approximately 10% risk of death from liver failure and/or require liver transplantation. In rare instances, the hepato toxicity can lead to chronic injury and vanishing bile duct syndrome. Given, sometimes very severe consequences of the adverse liver reactions, it cannot be over emphasized that the indication for the different antibiotics should be evidence-based and symptoms and signs of liver injury from the drugs should lead to prompt cessation of therapy [4].

Hepatotoxicity and drug- induced liver injury (DILI) are terms used interchangeably in this context. Drug- induced liver injury or DILI is the term currently used by most clinicians and scientists in this field. DILI can be defined as a liver injury induced by a drug or herbal medicines leading to liver test abnormalities or liver dysfunction with reasonable exclusion of other competing etiologies [5]. Most cases of DILI are due to idiosyncratic or unexpected reactions. In contrast to paracetamol- induced hepatotoxicity, which occurs with dose- dependent overdose of the drug, idiosyncratic drug reactions have been traditionally considered dose independent. However, drugs with well- documented idiosyncratic DILI have been shown to have a dose- dependent component [6].

**Theoretical background**

For most drugs, hepatotoxicity is extremely rare and has been estimated to occur from 1 in 10 000 to 1 in 100 000 of those exposed to the drug, and for other drugs, the risk is probably even lower<sup>7</sup>. The number of included patients in most clinical drug trials is less than 10000 and hepatotoxicity has been mostly detected in the post marketing phase. The frequency

of DILI among users of most drugs remains unknown and most epidemiological studies in this context suffer from major methodological limitations. There is uncertain accuracy in determining the relationship between the liver injury and the drugs reported in these studies. Most epidemiological studies are retrospective and lack standardized diagnostic work- up to exclude other potential causes of the liver injury. Moreover, most studies originate from tertiary referral centers and suffer from selection bias. Underreporting of adverse drug reactions is well known and DILI is no exception [8].

**Objectives of the study**

The main objective of the study is to find the drug induced liver injury in hepatic patients with special reference to Amoxicillin with the comparison of Clavulanate.

**Methodology of the study**

This study was conducted at the hospitals of Rahim Yar Khan, Pakistan during 2017 with the permission of ethical committee of hospital. For this purpose we select the 20 patients who was suffering from chronic hepatic injury due to the excessive use of drugs especially Amoxicillin and Clavulanate. Patients who suffer from DILI have a wide variety of clinical presentations. Clinically, biochemically and histologically, DILI can simulate almost all forms of acute and chronic liver injuries. Thus, these patients can present with acute liver failure with severe encephalopathy, with acute hepatitis with or without jaundice, and chronic hepatitis with both symptomatic and asymptomatic elevated liver tests.

**Histopathology of liver**

Tissues are fixed with neutral formalin 10%, embedded in paraffin, and then manually sectioned with a microtome to obtain 4-5  $\mu$ m-thick paraffin sections. Dewaxed sections are then stained with hematoxylin and eosin (H&E) or can be used for other purposes (special stains, immunohistochemistry, in situ hybridization, etc.). During this process, many steps and procedures are critical to ensure standard and interpretable sections. Key recommendations are given here to achieve this objective.

**Statistical analysis**

Student's t-test was performed to evaluate the differences in roughness between group P and S. Two-way ANOVA was performed to study the contributions. A chi-square test was used to examine the difference in the distribution of the fracture modes (SPSS 19.0 for Windows, SPSS Inc., USA).

**RESULTS:**

Table 1 shows the baseline characteristics of these patients. Also these subgroups of patients did not

reveal any significant differences between cases and controls, except for drug consumption.

**Table 01:** Analysis of characteristics of patients of both groups

Characteristic	Amoxicillin		Clavulanate	
	Cases n=7	P value	Cases n=13	P value
Sex, n (%)		0.09		0.14
Male	0 (0)		13 (59)	
Female	7 (100)		9 (41)	
Age (years), mean $\pm$ SD	42 $\pm$ 25.8	0.67	44.7 $\pm$ 17.8	0.65
BMI, mean $\pm$ SD	24.1 $\pm$ 6.8	0.77	24.6 $\pm$ 3.6	0.92
Alcohol, n (%)		0.99		0.51
Current drinker	4 (57)		16 (73)	
Former drinker	0 (0)		1 (4)	
Non-drinker	3 (43)		5 (23)	
Smoke, n (%)		0.17		0.99
Current smoker	3 (43)		7 (32)	
Former smoker	1 (34)		3 (14)	
Non-smoker	3 (43)		12 (54)	
Co-morbidities, n (%)				
Liver diseases	0 (0)	0.99	3 (14)	0.71
Heart diseases	2 (29)	0.99	2 (9)	0.99
Number of drugs, mean $\pm$ SD	6.9 $\pm$ 3.3	<0.001	4.9 $\pm$ 2.7	0.04

Table 2 shows the ANOVA results of both groups. It shows the degree of freedom and significant value of both groups with respect to control.

**Table 02:** ANOVA for drug induced hepatic injury

S.O.V	Sum of Squares	Df	Mean Squares	F	Sig.
Amoxicillin	12385.081	04	3096.270	23.794	.000
Clavulanate	2602.510	20	130.125		
Total	14987.591	24			

**DISCUSSION:**

Our data show that the combination of amoxicillin with clavulanic acid is significantly associated with a risk of DILI almost double compared to amoxicillin alone. The corresponding incidences are very low (0.1 cases for amoxicillin alone and 0.4 cases for amoxicillin +clavulanic acid for 100.000 inhabitants year, respectively), in line with other estimates from published data [9].

The amoxicillin component of the drug is primarily excreted by renal system, whereas clavulanic acid is excreted by both the kidney and liver [10]. The mechanism of co-amoxiclav induced hepatitis is not completely clarified, but the frequent association with hypersensitivity reactions (i.e. skin rash,

hypereosinophilia, anti-tissue antibodies) suggests an immune-allergic mechanism. The reaction could be due also to an idiosyncratic response to the drug [11]. Moreover, currently available evidence suggests a genetic susceptibility to coamoxiclav induced liver injury in patients with specific HLA haplotype. Although the absolute risk of co-amoxiclav-induced DILI is generally very low, as in the case of the present work, it must be also interpreted in relation to the widespread use of the drug, which continuously increased over the years [12]. In Italy, co-amoxiclav is the most prescribed antimicrobial agent (41% of total antibiotics use) and among the most prescribed drugs, both for adults and pediatric patients. In the period 2007-2015 co-amoxiclav use increased from 7.3 to 9.4 DDD/1000 inhabitants/day, whereas

amoxicillin use decreased from 3.9 to 2.1 [13]. These evidence raise concern regarding the inappropriate prescribing of co-amoxiclav in particular for respiratory tract infections, for which several international guidelines still recommended amoxicillin as first line antibiotic treatment [14]. Another aspect suggesting a certain degree of inappropriateness in the use of penicillins for infections of the respiratory tract is represented by the seasonal variation in the use of such drugs [15]. In fact, the Italian Report on the use of antibiotic drugs in 2009 showed a correlation between the monthly incidence of influenza cases and antibiotic consumption<sup>16</sup>. The treatment of disorders of viral origin with antibiotics is not only inappropriate, but can also substantially contribute to the development of antibiotic resistance [17].

### CONCLUSION:

It is concluded that compared to amoxicillin alone, amoxicillin +clavulanic acid doubles the risk of serious acute liver injury, in agreement with most studies on DILI.

### REFERENCES:

- Beraldo DO, Melo JF, Bonfim AV, Teixeira AA, Teixeira RA, et al. (2013) Acute cholestatic hepatitis caused by amoxicillin/clavulanate. *World J Gastroenterol* 19: 8789-8792.
- Bessone F, Hernandez N, Lucena MI, Andrade RJ(2016) The Latin American DILI registry experience: A successful ongoing collaborative strategic initiative. *Int J MolSci* 17: 313.
- Bolzan H, Spatola J, Castelletto R, Curciarello J (2000) Intrahepatic cholestasis induced by amoxicillin alone. *GastroenterolHepatol* 23: 237-239.
- RuizRebollo ML, Aller De La Fuente R, Macho Conesa A, SaladoValdivieso I, SainzGil M et al. (2011) Amoxicillin-induced cholestatic hepatitis. *GastroenterolHepatol* 34: 474-477.
- Chaabane NB, Safer L, Njim L, Zakhama A, SaffarH (2011) Cholestatic hepatitis related to amoxicillin. *Drug ChemToxicol* 34: 357-358.
- Berg P, Hahn EG (2001) Hepatotoxic reactions induced by beta-lactamase inhibitors. *Eur J Med Res* 6: 535-542.
- Rodríguez GLA, Stricker BH, Zimmerman HJ (1996) Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. *Arch Intern Med* 156: 1327-1332.
- Salvo F, Polimeni G, Moretti U, Conforti A, Leone R et al. (2007) Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. *J AntimicrobChemother* 60: 121-126.
- Donati M, Conforti A, Lenti MC, Capuano A, Bortolami O et al. (2016) Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. *Br J ClinPharmacol* 82: 238-248.
- Björnsson ES (2015) Drug-induced liver injury: an overview over the most critical compounds. *Arch Toxicol* 89: 327-334.
- Bénichou C (1990) Criteria of drug-induced liver disorders: Report of an international consensus meeting. *J Hepatol* 1: 272-276.
- Larrey D, Vial T, Micaleff A, Babany G, Morichau-Beauchant M et al. (1992) Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. *Gut* 33: 368-371.
- Larrey D (2002) Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. *Semin Liver Dis* 22: 145-156.
- Leise MD, Poterucha JJ, Talwalkar JA (2014) Drug-induced liver injury. *Mayo ClinProc* 89: 95-106.
- Van der Auwera P, Legrand JC (1985) Ticarcillin-clavulanic acid therapy in severe infections. *Drugs ExpClin Res* 11:805-813.
- <https://livertox.nih.gov/AmoxicillinClavulanate.htm>
- Dandakis D, Petrogiannopoulos C, Hartzoulakis G, Flevaris C, Lagoutari D et al. (2002) Cholestatic hepatitis associated with amoxycillinclavulanic acid combination. A case report. *Ann Gastroenterol*15: 85-87.
- Kim SH, Saide K, Farrell J, Faulkner L, Tailor A et al. (2015) Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. *Hepatology* 62: 887-899.
- Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP et al. (2011) Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology* 141: 338-347.
- Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M et al. (2010) Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. *J Hepatol* 53: 1049-1053.